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In the pursuit of improved diagnostic tests for infectious diseases, several classes of
molecules have been scrutinized as prospective biomarkers. Small (18–22 nucleotide),
non-coding RNA transcripts called microRNAs (miRNAs) have emerged as promising
candidates with extensive diagnostic potential, due to their role in numerous diseases,
previously established methods for quantitation and their stability within biofluids.
Despite efforts to identify, characterize and apply miRNA signatures as diagnostic
markers in a range of non-infectious diseases, their application in infectious disease has
advanced relatively slowly. Here, we outline the benefits that miRNA biomarkers offer to
the diagnosis, management, and treatment of infectious diseases. Investigation of these
novel biomarkers could advance the use of personalized medicine in infectious disease
treatment, which raises important considerations for validating their use as diagnostic or
prognostic markers. Finally, we discuss new and emerging miRNA detection platforms,
with a focus on rapid, point-of-care testing, to evaluate the benefits and obstacles of
miRNA biomarkers for infectious disease.
Keywords: microRNAs, infectious disease, diagnostics, biomarkers, personalized medicine
INFECTIOUS DISEASE DIAGNOSTICS: CURRENT OUTLOOK
Infectious diseases account for a large proportion of morbidity and 15% of total global mortality
(WHO, 2018a). Due to the ease of global travel and potential for global health epidemics, there is
a critical need for the early diagnosis of infected individuals to assist in containing the spread of
disease. For many diseases early intervention and expedient treatment is required for a favorable
prognosis. Sometimes clinical presentation or case history is sufficiently diagnostic, however,
choosing an appropriate course of treatment often relies upon the outcome of laboratory-based
diagnostic testing. The clinical diagnostic landscape for the detection of infectious diseases is diverse
and includes either looking for the pathogen or looking for the host’s response to the pathogen.
Conventional laboratory tests include in vitro culture and isolation, protein-based assays (for
example ELISA and serology), microscopy (histological, pathological, and morphological assays),
mass spectrometry (Kullolli et al., 2014) and molecular diagnostics which uses nucleic acid-based
assays (such as quantitative (q)PCR and sequencing). Many of these methods require a substantial
amount of time to perform and are reliant on intensive sample preparation, expert users, and suffer
from technical limitations.
Diagnostic tests might perform within acceptance criteria yet give the wrong answer, resulting
in either a false positive or false negative. This can be due to low sensitivity, low specificity, and/or
Frontiers in Microbiology | www.frontiersin.org 1 June 2020 | Volume 11 | Article 1197
fmicb-11-01197 June 3, 2020 Time: 16:19 # 2
Tribolet et al. MicroRNA Biomarkers of Infectious Diseases
not collecting a representative sample from the patient. In
some cases, infections can be localized to specific cell types or
tissues and a systemic sample, such as blood, may not contain
detectable levels of the pathogen required for detection. In
contrast, antibodies may be easily detected, however, antibody
responses may take weeks to months to manifest, with the
specificity of these responses sometimes hampered by cross-
reactivity (Lanciotti et al., 2008). Antibody testing can be suitable
for population level disease testing and analysis, to monitor
epidemic/pandemic spread and to ascertain which patients have
had prior exposure to a specific pathogen. Additionally, certain
viruses, including rabies (Ito et al., 2016) and cytomegalovirus
(Patro, 2019), efficiently modulate or evade the immune response,
further complicating their detection. Tests for some pathogens
are also ineffective during the early phases of infection. For
example, the gold-standard diagnostic test for rabies (lyssavirus)
infection is a fluorescent antibody test that can only be performed
on post-mortem brain tissue. Other classes of diagnostic
molecules include other nucleic acids such as messenger RNA
(mRNA) for the detection of urothelial carcinoma (Urquidi et al.,
2016), proteins such as procalcitonin (PCT) interleukin-6 (IL-
6) and C-reactive protein (CRP) for sepsis (Lai et al., 2020)
the presence of metabolites such as creatinine in serum or urea
for renal disease (Stevens et al., 2006) or even presence of
volatile compounds in breath analytics are being tested as cancer
diagnostics (Markar et al., 2016).
In the search for new diagnostic biomarkers to circumvent
these issues, many different classes of molecules have been
studied. Amongst the most promising are microRNAs (miRNAs),
small (18–22nt) non-coding RNA molecules found within all
bodily fluids and tissues and most cell types (Halushka et al.,
2018), which play an essential role in post-transcriptional
regulation of gene expression. There are approximately 2,600
miRNAs in the human genome thus far according to the online
miRNA repository, miRbase (version 221) and approximately
2,000 miRNAs in circulation (Juzenas et al., 2017). MicroRNAs
are named with the miR prefix followed by an identifying
number. If there are extremely similar sequences, additional
suffixes (letters or numbers) are provided. Older nomenclature
can also refer to a miRNA as the guide (used to identify target
mRNA) or passenger (denoted with a ‘∗’ suffix) miRNA. As more
studies demonstrated that both strands can be functional (Jin
et al., 2015; Gao et al., 2020), this was replaced with the use of
-3p and -5p suffixes, denoting the 3′ or 5′ end of the miRNA
precursor. For an in-depth review of miRNA biogenesis and
function, please see Saliminejad et al. (2019).
THE POTENTIAL FOR miRNAs TO
IMPROVE DISEASE OUTCOMES
In 2002, less than a decade after the discovery of miRNAs
(Lee et al., 1993), the application of miRNAs as disease
biomarkers was first explored. Calin et al. (2002) showed that
miRNA expression patterns were altered in patients suffering
1http://www.mirbase.org/
from chronic lymphocytic leukemia. Shortly after this, miRNA
expression was found to change during tumorigenesis (Michael
et al., 2003), and could be successfully used to classify multiple
human cancers (Lu et al., 2005). Since then, studies have
examined the potential of miRNAs as biomarkers of diabetes
(Farr et al., 2013, 2015a,b), Alzheimer’s Disease (Lugli et al.,
2015), and numerous other non-infectious conditions. Meta-
analyses of multiple cancer studies strongly support a role
for miRNAs as diagnostic, providing the ability to identify a
disease (Zhi et al., 2015) or prognostic, identifying the likelihood
of developing specific disease outcomes (Schmitz et al., 2016)
biomarkers. Additionally, miRNAs may extend the clinical utility
of current proteins or metabolite-based tests. For instance,
a recent paper demonstrated that miR-29a and miR-335 in
combination with matrix metalloprotease protein-2 (MMP2),
proved to be a superior diagnostic in breast cancer to the current
carcinoembryonic antigen (CEA) and cancer antigen 15-3 (CA
15-3) tests that are widely used (Ali Ahmed et al., 2020).
Recently, several reports describe changes in circulating
miRNAs in response to infectious diseases, raising the possibility
for a new diagnostic tool against infections. MicroRNAs have
been identified as potential biomarkers of infections caused by
a range of pathogens, including Hendra virus (Stewart et al.,
2013), HIV (Biswas et al., 2019), tuberculosis (Zhang et al., 2013),
malaria (Li et al., 2018), including differentiating complicated and
uncomplicated P. vivax malaria (Kaur et al., 2018) and Ebola
(Duy et al., 2016). In some studies, changes in miRNA profiles
were observed early in disease onset, before the pathogen could
be directly detected and prior to the onset of seroconversion
(Stewart et al., 2013; Biswas et al., 2019). MicroRNAs have
also been implicated in influenza infections (Scheller et al.,
2019) and rhinoviruses (Hasegawa et al., 2018). Therefore,
the potential for miRNA diagnostics with other respiratory
viruses, such as the recent severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) outbreak, is not to be understated.
An identified and validated COVID-19 miRNA signature could
provide differential diagnosis to identify COVID-19 infections
from other infections with similar presenting symptoms such
as influenza, rhinoviruses or other coronaviruses. Additionally,
as mentioned above miRNAs have prognostic potential, to
identify the likelihood of severe vs. mild disease outcomes and
also to identify asymptomatic infections (Hou et al., 2017),
which are problematic in epidemic or pandemic spread and
disease tracking.
The potential utility of these molecules as diagnostic
biomarkers is enhanced by their presence and stability in a wide
range of biological fluids, including peripheral circulation. They
show remarkable stability despite multiple freeze-thaw cycles
or extreme pH (Chen et al., 2008) and are routinely measured
via next generation sequencing (NGS) or qPCR (Farr et al.,
2015a). Despite this, there are many infectious diseases for which
miRNA biomarkers would be inappropriate, ineffectual, or highly
difficult to implement in clinical practice. For example, short-
term, self-limiting infections that require minimal intervention
(apart from alleviating symptoms), such as the common cold or
gastroenteritis, would not benefit from the development of these
biomarkers. Others, particularly those with significant impact,
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currently sub-par diagnostics, or long subclinical phases would
benefit greatly by the application of validated miRNA diagnostics.
Therefore, it is important to understand the disease of interest
and how miRNA biomarkers would be best applied before
embarking on miRNA biomarker discovery.
Advantages of miRNA Biomarkers I:
Early Detection
The early detection of infectious disease is often critical to
improve patient prognosis and limit the spread of disease.
Treatment options often become increasingly limited as a disease
proceeds (Wagstaff et al., 1994; McLean et al., 2015) (Figure 1).
Rabies is a classic example of a disease where early intervention
is crucial; it has an extremely long asymptomatic period of 2–
3 months on average and once symptoms appear it is almost
FIGURE 1 | MicroRNA signatures during infection. Infections typically
progress through three stages: (1) incubation (green), where the pathogen is
present and replicating but the patient is asymptomatic, (2) prodromal (blue),
where the pathogen continues to replicate (white line) and causes
non-specific symptoms due to immune activation, and (3) clinical illness
(orange), where the symptoms of disease are the most severe. As the
infection progresses through these stages treatment options often become
more limited (red dashed line). Released miRNAs may reflect the stage of
disease and provide important clinical information, particularly when the
causative pathogen is difficult to detect.
always fatal (WHO, 2019). Therefore, early intervention is
key to survival.
Post-mortem brain smears are the current ‘gold standard’
diagnostic test for rabies infection, as the virus’ ability to evade
the immune system and reside within neurons make standard
molecular diagnostics difficult. Changes in miRNA profiles from
rabies infected brain tissue have been documented and offer
a promising insight into the miRNA response to lyssavirus
infection (Zhao et al., 2012; Qi et al., 2014). However, there
has only been one study examining the release of miRNAs into
peripheral circulation due to lyssavirus infection. This study,
completed in a mouse model, found seven miRNAs (miR-100,
-187, -322, -706, -466, and -98) that were altered in the serum
of infected mice compared to uninfected controls (Han et al.,
2011). Low numbers of animals (only 3 control animals) and
a heterogeneity in viral RNA and protein expression (measured
via immunofluorescence, ELISA and nested RT-PCR) means that
this work needs to be further validated. This hypothesis would
also require testing in a model system that better replicates
miRNA regulation in humans in order to translate miRNA
profiling into a diagnostic tool for at-risk individuals.
Human immunodeficiency virus (HIV) is another well-known
virus that would benefit from early detection. Infection with HIV
causes systemic T-cell destruction and a corresponding reduction
in cell mediated immunity (acquired immunodeficiency
syndrome, AIDS) (Moir et al., 2011). It also results in damage to
many organs through endothelial cell dysfunction and immune
activation. As a result, there are numerous diseases associated
with HIV infection, including viral and bacterial infections,
cancers, encephalitis, gut disease, and cardiac damage (Lucas
and Nelson, 2015). While the mortality rate from HIV-AIDS is
decreasing, AIDS-related disease is still the leading cause of death
in persons with HIV (Smith et al., 2014). The wide, and often
devastating, impact of HIV infection has prompted numerous
studies identifying miRNA biomarkers of both HIV infection
and AIDS-related diseases.
Serum miR-21, -122, and -223 were found to distinguish
HIV-positive from HIV-negative groups with a moderate (0.773,
0.726, and 0.804, respectively) receiver operating characteristic
(ROC) area under the curve (AUC) (Thapa et al., 2014).
A ROC AUC gives a succinct measure of the overall diagnostic
accuracy of a test, with values typically ranging from 0.5 (no
discrimination between groups) to 1 (perfect discrimination).
For an in-depth review of ROC curves in evaluating diagnostic
test accuracy, please see Hajian-Tilaki (2013). MicroRNA-3162-
3p abundance in plasma from HIV patients was shown to
differentiate new (<1 year post-infection) from old (>1 year)
infections (Huang et al., 2018). Interestingly, a study by Yahyaei
et al. (2016) found that miR-223 and -29a were elevated in
individuals that were repeatedly exposed to HIV but did not
contract a productive infection. These miRNAs may be purely
markers of viral exposure or may play a key role in HIV
resistance. Recently, a panel of four miRNAs (miR-16-5p, -
20b-5p, -195-5p, and -223-3p) was developed and tested for
HIV diagnostic utility (Biswas et al., 2019). Blind testing was
able to identify all positive samples and healthy controls with
100% sensitivity and specificity. A different combination of four
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miRNAs (miR-16-5p, -206, -181c-3p, and let-7g-3p) were able to
detect the eclipse phase of infection (the period of time between
exposure and reliable diagnostic detection) with 100% sensitivity,
95.8% specificity, and a ROC AUC of 0.999. This highlights the
use of miRNAs as disease biomarkers during the infectious period
where conventional markers (antibodies, viral RNA/protein) are
consistently undetectable (Biswas et al., 2019). Early therapeutic
intervention in HIV infection has been shown to lead to long-
term control of the infection with very low levels of persistent
viremia (Nishimura et al., 2017).
Early detection can aid in quarantine, surveillance and
biocontainment, factors that are especially relevant for diseases
capable of being transmitted from animals to humans. Hendra
virus (HeV) is a zoonotic paramyxovirus that can cause severe
and often fatal infections in humans. The natural reservoir
host for HeV is pteropid fruit bats, however, in 1994 it spilled
over to horses and then humans (all with close contact to the
infected horses) (Murray et al., 1995). Numerous outbreaks of
HeV have occurred in Australia, mainly in horses, sparking
concerns for human health. Stewart et al. (2013) identified
elevated levels of miR-146a in the blood of experimentally
challenged horses and ferrets (a model for human disease).
This elevation was found to occur days before the detection
of the viral genome. A subsequent study took an unbiased
NGS-based approach to profile miRNAs within the blood of
infected horses and found that 37 miRNAs were significantly
altered in the blood of infected horses relative to healthy controls
(Cowled et al., 2017). This study also examined the potential
use of ratios of miRNAs, rather than individual abundances,
to distinguish infected from uninfected animals. By doing so,
inter-replicate variability was minimized, offering an alternative
and possibly more robust method of identifying diagnostic
miRNA signatures.
Advantages of miRNA Biomarkers II:
Improved Pathogen Identification
When symptoms of infectious diseases first appear, they are
often non-specific (fever, malaise, headache, and lethargy) and
provide little to no information about the causative agent.
Consequently, clinicians may misdiagnose patients, which may
have severe downstream consequences. One such example
of this is viral encephalitis, where symptoms progress from
an influenza-like illness to severe neurological abnormalities,
including convulsion, speech loss, confusion, and coma.
There are numerous neurotropic viruses that can cause viral
encephalitis, ranging from common well-known agents,
including herpes simplex virus (HSV), varicella-zoster virus
(VSV), and enteroviruses, to deadly zoonotic pathogens such as
Japanese encephalitis virus (JEV), lyssavirus (rabies), Nipah virus
(NiV), and Hendra virus (HeV).
Although best known for being the causative agent of cold
sores and genital warts, HSV is also the most common cause
of viral encephalitis (Rabinstein, 2017). Serotype HSV-1, is one
of the most intensively studied viruses, and is often used as the
representative member of the alpha-herpesvirus subfamily. It was
this intense scrutiny that led to the discovery of HSV-encoded
miRNAs in 2006 by Cui et al. (2006). These miRNAs were found
to be highly expressed during active infection (miR-H1) (Cui
et al., 2006) and latency (miR-H2-6) (Umbach et al., 2008), and
are actively packaged into exosomes and exported to uninfected
cells (Kalamvoki et al., 2014). Despite no study outlining the use
of these as diagnostic markers of HSV infection, these molecules
have potential as biomarkers due to the specificity of these
virally encoded miRNAs.
Recently, VSV has also been found to encode multiple small
non-coding RNAs (Markus et al., 2017), however, these have
not yet been found within the extracellular milieu. Clinically,
VSV causes varicella (chickenpox) during the initial infection,
but then becomes latent within dorsal root ganglion and cranial
nerves and can reactivate to cause herpes zoster (shingles)
(Gershon et al., 2015). A study Qi et al. (2014) found that
several host miRNAs were altered in the serum of unvaccinated
children with varicella compared to healthy controls. Five of
these molecules, miR-197, -629, -363, -132, and -122, were
found to differentiate VSV-infected individuals from controls,
with a ROC AUC of 0.872. This combination of miRNAs could
also distinguish the VSV-infected patients from others infected
with similar pathogens, including pertussis (whooping cough),
measles, and enteroviruses (Qi et al., 2014). Another study in
2016 found a further six miRNAs (miR-190b, -571, -1276, -
1303, -943, and -661) that were differentially expressed in the
serum of patients with reactivated herpes zoster (Li et al., 2016).
Combined, these miRNAs could distinguish patients with herpes
zoster from healthy controls and individuals infected with HSV,
with a ROC AUC of 0.939 (Li et al., 2016).
Similarly, serum miRNA profiling of children with hand, foot
and mouth disease (HFMD), caused by enteroviral infection,
identified six miRNAs (miR-148a, -143, -324-3p, -628-3p, -
140-5p, and -362-3p) that were able to discriminate between
infected and healthy controls with a combined ROC AUC
of 0.989, a sensitivity of 97.1% and a specificity of 92.7%
(Cui et al., 2011). These miRNAs also displayed a unique
profile between enterovirus and other microbial infections,
including tuberculosis, pertussis, measles, mumps, and varicella.
Interestingly, miR-140-5p was undetectable in healthy controls
but was easily detectable in the serum of patients infected
with any of the six pathogens investigated (Cui et al., 2011).
Furthermore, five miRNAs (miR-148a, -143, -324-3p, -545,
and -140-5p) were significantly altered between the two major
causative agents of HFMD, coxsackievirus-16 and enterovirus-
71, and demonstrated a moderate ability to distinguish between
the two enteroviruses (combined ROC AUC of 0.761) (Cui
et al., 2011). These results strengthen the hypothesis that miRNA
biomarkers cannot only identify infected from uninfected
individuals, but also distinguish between different causative
agents. Further details on the potential of miRNAs in infectious
disease diagnostics can be found in Ojha et al. (2019).
Advantages of miRNA Biomarkers III:
Detection of Latent Infections
Latency periods present significant hurdles in the current
medical landscape. During these periods, the pathogen is
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present but cannot be detected via routine diagnostic methods.
While the patient appears healthy, the pathogen can reactivate
at any time, causing clinical disease or shedding infectious
material. Tuberculosis (TB) is the leading infectious cause of
death worldwide but healthcare efforts are often hampered
by the large number of individuals with latent infections
(WHO, 2018b). It is estimated that 23% of the global
population have a latent TB infection, and 5–10% of these
will develop active infection and clinical disease (WHO,
2018b). As there are currently no diagnostic platforms for
latent TB, it is recommended to provide treatment to priority
groups, including people living with HIV and children under
5 years old living with someone with confirmed TB (household
contacts) (WHO, 2018b).
Several studies have identified circulating miRNAs in active
pulmonary TB (Fu et al., 2011; Zhang et al., 2013; Cui et al.,
2017; Barry et al., 2018; Pedersen et al., 2019). Recently, Lyu
et al. (2019) examined exosomal miRNAs from the serum of
patients with active and latent TB infections, as well as healthy
controls. They found miRNA expression patterns unique to each
group, including four miRNAs (let-7e-5p, let-7d-5p, miR-450a-
5p, and miR-140-5p) that were elevated in latent TB infection
when compared to both active infection and healthy controls
(Lyu et al., 2019). Although their utility as diagnostic markers
was not fully explored, they highlight the potential of miRNAs
to identify latent TB infection. Circulating miRNAs have also
been found to predict whether adults exposed to TB via infected
household contacts would progress to active infection within the
next 6 months (Duffy et al., 2018). These prognostic markers
could be used to identify people at higher risk and better
target the use of prophylactic treatments. At the opposite end
of the TB infection timeline, researchers found four serum
miRNAs that were able to identify patients who were cured of
TB infection with an accuracy of 83.96% (Wang et al., 2018).
Being able to discriminate between resolved and latent infections
would provide clinicians with essential information to guide
decisions for treatment and management of TB. COVID-19,
another pulmonary disease where latency of up to 2 weeks and
asymptomatic infections are a recognized problem (Jiang et al.,
2020), is another disease where a more effective and accurate
diagnostic is needed.
Advantages of miRNA Biomarkers IV:
Personalized Medicine
Disease severity and the efficacy of anti-infective therapies
can vary markedly between patients. Personalized medicine
(also known as precision medicine or theranostics) recognizes
that a ‘one size fits all’ approach is not always effective
and attempts to tailor the treatment to achieve the best
clinical outcomes. This healthcare concept is underpinned
by biomarkers to provide pertinent information for timely
and effective treatment decisions (Figure 2). Biomarkers
in the field of personalized medicine often refer to an
individual’s genotype, such as the BRCA mutation in
ovarian cancer (Marchetti et al., 2018), however, this
idea is being extended to other diagnostic or prognostic
markers, such as miRNAs. As with many aspects of
medicine, this approach first gained traction in oncology
(Liu et al., 2014) but is now spreading to other areas, including
infectious diseases.
Malaria is one such disease that results in a spectrum of
severity, from asymptomatic to fatal infection. Recently, Burel
et al. (2017) utilized a controlled human infection model to
investigate the early molecular responses to malaria infection.
They found that infected individuals could be stratified into
two groups based on the changes in their circulating miRNA
profile (low and high miR responders). Those patients in the
high miR group were found to have increased CD4+ T-cell
activation, a more robust antibody response, and reduced parasite
burden (Burel et al., 2017). Importantly, the authors defined
three miRNAs (miR-15a-3p, -30c-5p, and -30e-5p) that could
distinguish these high and low-miR responders within days post-
infection (Burel et al., 2017). These changes provide important
information about the individual’s response to infection, helping
to identify high-risk patients and guide treatment decisions. This
divergent immune reaction may also explain the mixed success in
malaria vaccine development (Rts, 2015).
Patients can also demonstrate a wide range of responses to
therapeutic intervention, which can impact a clinician’s ability
to provide an accurate prognosis. For example, 30–50% of
individuals infected with hepatitis C virus (HCV) will not
respond effectively to antiviral treatment (Cavalcante and Lyra,
2015). A liver-enriched miRNA, miR-122, has been shown to
predict the efficacy of HCV therapy better than traditional
circulating biomarkers, including alanine aminotransferase
(ALT), albumin, and HCV RNA (Fan et al., 2017). Furthermore,
circulating miR-122 was found to decrease alongside detectable
HCV RNA during antiviral therapy, reflecting successful HCV
treatment (Koberle et al., 2013). These results support the use of
this miRNA to monitor the progression of HCV infection, predict
treatment efficacy, and aid in prognostic accuracy.
Whilst much of this manuscript details the use of miRNA
biomarkers in a diagnostic sense, the studies mentioned above
highlight the potential of miRNAs to measure treatment efficacy,
predict disease outcome and host responses, and guide optimal
therapeutic selections as companion diagnostics.
CAVEATS OF miRNA BIOMARKERS
The development of host miRNAs as infectious disease
biomarkers will require the successful navigation of several
hurdles. Principle among these is the perceived lack of specificity
among miRNAs responding to diverse infections. For example,
miR-146a expression is known to fluctuate in response to
hepatitis B virus (Wang et al., 2019), HCV (Abdel Motaleb et al.,
2017), schistosomiasis (Cai et al., 2018), malaria (Cohen et al.,
2018), JEV (Baluni et al., 2018), HeV (Stewart et al., 2013), and
even prion disease (Bellingham et al., 2012). This miRNA has
also been identified in non-infectious diseases, such as diabetes
(Farr et al., 2015b) and heart disease (Quan et al., 2018). On its
own, miR-146a has minimal disease specificity; indeed, it may be
only indicative of a general immune response related to activation
of the NF-κB transcription factor (Testa et al., 2017). However,
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this does not mean it should be disregarded, as the immune
response may be an important marker of disease. Instead, miR-
146a should be measured in conjunction with additional disease-
specific miRNAs to ensure diagnostic accuracy.
Generalized miRNA responses to infection has important
implications when trying to use these biomarkers to diagnose
infections in the presence of co-morbidities or co-infections that
may confound the results. Although there are studies that explore
miRNA signatures in known co-infections, such as HIV/HCV
(Anadol et al., 2015), this data is limited and is not able to take
into account unknown confounding factors. Increasing biological
replicates for miRNA biomarker discovery studies, as well as
careful validation studies, will help to mitigate this issue and
result in a more robust diagnostic signature.
Many studies identify potential miRNA biomarkers as those
whose abundance changes in biofluids, utilizing a statistical cut-
off to justify their selections. This approach, while effective in
identifying large scale changes, does not automatically select for
the most diagnostically relevant miRNAs. Instead, the degree
of variation or the relationship of one miRNA to another may
provide more effective differentiation between infected and non-
infected individuals. Cowled et al. (2017) found that using ratios
of two miRNAs ( miR_AmiR_B ) improved the adjusted P-values by
normalizing for individual heterogeneity. Notably, these ratios
were not arbitrarily selected; every possible combination of
miRNAs was tested to identify those ratios that had the most
statistically significant difference between groups. The use of
miRNA ratios will have limited impact on their use in a clinical
setting compared to the absolute or relative levels of a single
marker. Indeed, they would be measured in concert (using a
multiplex approach), the ratio calculated, and result presented
based on whether they cross a pre-defined threshold.
This application of advanced bioinformatic analysis tools
gives researchers more robust methods of identifying and
evaluating predictive miRNAs. Feature selection algorithms
(Saeys et al., 2007; Wang et al., 2016) allow computers
to trawl through datasets highlighting the most predictive
miRNAs, and have become more integral as researchers
generate larger, more complex datasets. The introduction of
machine learning into biological sciences has meant that
researchers can create computational models that evaluate the
predictive power of miRNA candidates on blinded samples.
This approach can identify complex patterns and strengthen
diagnostic classification. Machine learning has already been
used to identify miRNA biomarkers for Ebola virus and
Mycobacterium tuberculosis (Duy et al., 2016; Duffy et al., 2018)
and will likely become more widespread. For this to occur, more
investment needs to be made in advanced data analytics for
biological sciences. In particular, microRNA biomarker research
should move beyond simple differential expression analysis to
capture the full spectrum of permutations and subtleties in
expression of these molecules. Two factors that will greatly
enhance successful outcomes from the use of computational
analysis are: (1) an immediate focus on higher replicate numbers,
and (2) proper use of holdout sets (validation samples),
independent of samples used for initial biomarker discovery
(training sets). These multivariate approaches (including the
use of ratios) aid in the identification of composite miRNA
signatures that can mitigate the lack of specificity seen in some
individual markers.
Finally, despite advances in the rapidly advancing field of
miRNA detection (Cheng et al., 2018; Kalogianni et al., 2018;
Kilic et al., 2018), there are currently no industry standards for
the detection and quantification of miRNAs for clinical diagnosis
of disease. This handicap is due to the nature of miRNAs as
diagnostic targets; they require isolation from biological fluids
prior to detection; tend to exhibit subtle nucleotide differences
leading to complications in probe specificity; and need to
be protected from RNAse degradation during handling and
processing (De Guire et al., 2013). In the future, emerging
technologies for sample preparation and the detection of miRNAs
for the diagnosis of infectious diseases should assist to improve
current use of miRNAs as diagnostic markers.
CURRENT AND FUTURE TRENDS IN
miRNA DETECTION SYSTEMS
Current miRNA Detection Platforms
Conventional approaches to the detection of miRNAs include
northern blotting, microarrays, qPCR, and next generation
sequencing (NGS). Contemporary miRNA biomarker studies
tend to utilize qPCR and NGS, with northern blotting and
microarrays falling out of favor due to limitations, including
low sensitivity or specificity, and higher total RNA input
requirements (often several micrograms for northern blotting).
Recently, researchers have utilized Mass Spectrometry (MS) for
the detection of miRs (Kullolli et al., 2014). Several reviews
address qPCR and NGS for miRNA detection (Hardikar et al.,
2014; Vincent et al., 2017).
To quantitate via qPCR, miRNAs are reverse-transcribed to
cDNA and then amplified using defined primers. A sequence-
specific probe, which contains a fluorophore and quencher,
binds to the cDNA, and during amplification is cleaved by the
endonuclease activity of the DNA polymerase. This releases the
fluorophore and the resulting fluorescence is measured (Wong
et al., 2015). It is a highly sensitive, highly specific gold standard
against which to evaluate other detection systems. Despite its
utility, qPCR suffers from several limitations, namely it is
relatively expensive, and requires a priori defined primer and
probe sequences. It is also relatively low-throughput, although
this can be partially addressed through robotic handling systems,
multiplexing and qPCR arrays (Wong et al., 2015).
Next generation sequencing also requires reverse-
transcription and amplification but does so without using
primers or probes specific to known miRNAs. It yields millions
of short read sequences that can then be either analyzed de novo
or mapped to a reference sequence such as a genome or miRNA
sequence database (miRbase) (Kozomara et al., 2019). This
technique allows quantitation of all miRNAs present in a sample,
even novel sequences. Numerous NGS platforms are available
with various proprietary chemistries but all are bulky, expensive
(although prices are continuing to fall), time-consuming, and
require complex sample preparation, instrument operation, and
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data analysis procedures. Despite this, it is the technique of
choice for initial discovery of miRNA biomarkers and is typically
followed by development of qPCR assays for further validation.
New and Emerging miRNA Detection
Platforms
Emerging technologies for the detection of miRNA biomarkers
in infectious diseases aim to improve upon what is currently
available, focusing on one or more of the following
characteristics: portable, reliable, robust, rapid, specific,
sensitive, low-cost, and user-friendly. Transitioning from costly
and time-consuming lab-based methodologies to point-of-care
(PoC) technologies is particularly important for the diagnosis
and management of infectious disease outbreaks, where accurate
and timely identification of infected individuals in resource-
limited environments is critical for both patient care and
disease containment.
As the current in-lab miRNA detection technologies continue
to improve, the next question is how to translate this technology
into PoC devices, and how to improve the current protocols in
such a way that they are easily translatable. The predominant
barrier to the development of PoC devices for miR detection
is the low concentration of miRs in most biofluids. Whilst the
concentration of individual miRs vary significantly in different
biofluids, in healthy individuals, miRs in plasma are generally
present in the fM range (9,000–134,000 copies/µL) (Mitchell
et al., 2008). To overcome this, most examples of miRNA
detection rely upon complex miRNA extraction protocols (such
as multiple centrifugation or pipetting steps) or highly complex
and bulky detection instrumentation (such as high-throughput
NGS platforms or MS-based techniques) that are impractical
for use in a resource limited PoC environment. To counteract
this, many researchers have begun to develop new technologies
that focus on miRNA extraction and detection in portable
devices. An overview of these technologies can be found in
Figure 3, while Table 1 compares their attributes. Whilst
most of these examples focus on the diagnosis of cancer in
humans, all of the technologies could be easily adapted to
the diagnosis of infectious disease by modifying the target
sequences of interest.
Lateral flow devices (strip tests) are useful tools for robust
detection of biomarkers at the PoC due to their low-cost,
simplicity, portability and specificity. In light of this, numerous
groups have developed strip-based biosensors for miRNA
detection (Hou et al., 2012; Gao et al., 2014; Deng et al., 2017a).
Given most medical diagnoses are made after testing a panel
of two or more biomarkers, Zheng et al. (2018) developed a
multiplexed lateral flow assay for the simultaneous detection
of miR-21, miR-155 and miR-210 in human serum samples at
concentrations as low as 68, 7, and 17 pM, respectively, within
10 min (Figure 3A).
Deng et al. (2017a) sought to overcome the limited sensitivity
of previous lateral flow based biosensors by incorporating a
target recycling amplification strategy, whereby two sequence
specific hairpins are used to amplify the signal without the
need for added enzymes. The improved sensing mechanism
FIGURE 2 | MicroRNA biomarkers in personalized medicine. Many infections
result in a spectrum of disease severity, including asymptomatic (black), mild
(red), and severe (blue) disease. Circulating miRNA signatures may
differentiate between these groups and their ultimate disease outcome. This
information would allow clinicians to tailor their approach and provide optimal
therapeutic interventions.
required incubation at 37◦C for 60 min and additional equipment
including a handheld UV-light and mobile phone/digital camera
but boasted a remarkable LOD of 200 attomoles from 20 µL of
sample within 80 min.
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FIGURE 3 | Representative approaches to the development of PoC miRNA sensing devices. (A) Lateral flow test device. Reprinted from Sensors and Actuators B:
Chemical, volume 264, Zheng et al. (2018). Lateral flow test for visual detection of multiple MicroRNAs, Pages 320–326, Copyright (2018), with permission from
Elsevier. (B) Electrochemical biosensor. Reprinted with permission from Labib et al. (2013a). Four-Way Junction Formation Promoting Ultrasensitive Electrochemical
Detection of MicroRNA. Analytical Chemistry 85(20), 9,422–9,427. doi: 10.1021/ac402416z. Copyright (2013) American Chemical Society. (C) µPAD for miRNA
extraction and quantitation. Reprinted with permission from Deng et al. (2017b). Paperfluidic Chip Device for Small RNA Extraction, Amplification, and Multiplexed
Analysis. ACS applied materials interfaces 9(47), 41,151–41,158. doi: 10.1021/acsami.7b12637. Copyright (2017) American Chemical Society. (D) Colorimetric
miRNA sensing strategy. Reprinted with permission from Feng et al. (2017). Detection of microRNA: a point-of-care testing method based on a pH-responsive and
highly efficient isothermal amplification. Analytical chemistry 89(12), 6,631–6,636. doi: 10.1021/acs.analchem.7b00850. Copyright (2017) American Chemical
Society.
Fully integrated patterned paper-based microfluidic devices
(µPADs) have been developed featuring simple, user-friendly,
robust and low-cost solutions for determination of a range of
biomarkers using a variety of fabrication and detection strategies
(Dungchai et al., 2009; Delaney et al., 2011; Dungchai et al., 2011).
µPADs are particularly promising for the diagnosis of infectious
diseases in resource limited settings as they are single-use, low-
cost and can be readily disposed of by incineration; this negates
the need for extensive sterilization procedures thus reducing the
risks of accidental infection or contamination.
A variety of µPADs have been developed for PoC miRNA
detection (Deng et al., 2017b) (Figure 3C). Deng et al. (2017b)
inspired by previous examples of paper-based nucleic acid
extraction (Connelly et al., 2015; Rodriguez et al., 2015),
developed two paper based devices – one for miRNA extraction
and amplification and a second for detection of the miRNA –
which could be easily interfaced using magnetic sheets. The
extraction and detection procedures required only a heating
block for isothermal amplification, UV-light for quantum dot
excitation and digital camera/mobile phone for fluorescence
detection (Deng et al., 2017b). The µPAD exhibited a LOD of
3 × 106 copies for two miRNAs (miR-21 and miR-155) from
tumor cell lysate (Deng et al., 2017b). The simplicity, speed
(90 min time-to-result) and low-cost of this paper-based device
make it an ideal candidate for the diagnosis of infectious disease.
In spite of the application of µPADs for a variety of sensing
applications, they are inherently limited in fluorescence-based
sensing applications due to high background fluorescence and
light scattering from the paper substrate (Pelton, 2009; Nery
and Kubota, 2013). To overcome the challenges of conducting
fluorescence assays on paper, Liang et al. (2017) grew a flower-
like silver (FLS) layer on the paper substrate which decreased
background fluorescence and produced ‘hot-spots’ where surface
enhanced fluorescence of carbon nanodot labeled probes was
observed. A detection limit of 30 and 60 aM was observed for
miR-210 and miR-21, respectively, using the FLS µPAD. The
device was also used for a qualitative visual pre-screening of
analyte concentration due to a color change after the addition
of hydrogen peroxide that caused oxidation of clear Ce3+
labels to orange Ce4+ (Das et al., 2007; Sardesai et al., 2013;
Liang et al., 2017).
Visually identifiable color changes provide the simplest and
lowest-cost detection strategy available. Inspired by the simplicity
of the color-coded pH test strip Feng et al. (2017) exploited the
production of hydrogen ions (H+) as a by-product of netlike
rolling circle amplification (NRCA) to develop a pH dependent
visual miRNA sensing methodology (Figure 3D). The group
employed three pH indicators – cresol red, neutral red and
m-cresol purple – and observed an LOD of 100 femtomolar
(fM) for miR-21 by visual observation of the color change
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TABLE 1 | Selected examples of emerging miRNA detection platforms.
References Detection Sample LOD Multiplexed Amplification
Lateral flow
Gao et al., 2014 Visual/photographic Cell lysate 60 pM No No
Deng et al., 2017a Visual/cell phone/digital camera Cell lysate 200 attomoles (10 pM)a No Target–recycled
non-enzymatic amplification
Zheng et al., 2018 Visual/photographic Human serum 7–85 pM (quantitative)
10–50 pM (visual)
3 No
Electrochemical
Cardoso et al., 2016 Electrochemical impedance
spectroscopy (EIS) and square
wave voltammetry (SWV)
Human serum 5.7 aM No No
Labib et al., 2013a SWV Human serum 2 aM No No
Labib et al., 2013b SWV and EIS Human serum 5 aM No No
Gai et al., 2018 Open circuit voltage Human serum 2.7 aM No No
Cheng et al., 2015 SWV Human serum 0.76 aM No No
µPAD
Deng et al., 2017b Visual/cell phone/digital camera Cell lysate 3 × 106 copies (996
fM)b
2 Hairpin probe-exponential
amplification reaction
Liang et al., 2017 Visual/fluorescence spectrometer Cell lysate 30–60 aM 2 No
Colorimetric
Feng et al., 2017 Visual/UV-Vis Cell lysate 100 fM (Visual) 9.3 fM
(UV-Vis)
No Netlike rolling circle
amplification
Digital Microfluidic
Giuffrida et al., 2015 Fluorescence microscope Cell lysate 3.3 attomoles (165 pM) No Molecular-beacon (MB)-
assisted isothermal
circular-strand-displacement
polymerization
Shamsi et al., 2016 Electrochemiluminescence
photomultiplier tube
Cell lysate 1.5 femtomoles
(1.1 nM)
No No
aLOD concentration calculated from 20 µL sample volume from Deng et al., 2017a. bLOC concentration calculated from 5 µL sample volume from Deng et al. (2017b).
with the naked eye using a commercially available pH test
strip or color indicator solution Where required, the samples
could subsequently be analyzed via UV-Visible spectroscopy for
quantitative sample analysis.
Whilst the majority of PoC sensing applications have
focused on the development of colorimetric or fluorescence
read-out strategies, these methodologies suffer from several
drawbacks including high background signals which limit
sensitivity. Numerous researchers have sought to overcome this
drawback by employing less conventional detection strategies
with interesting results.
Digital microfluidic (DMF) devices employ software-based
electronic control of liquids and offer numerous advantages
over conventional microfluidic systems as they eliminate the
need for tubing and pumps whilst maximizing automation and
reducing sample volumes (Choi et al., 2012; Giuffrida et al., 2015).
Shamsi et al. (2016) employed electrochemiluminescence in a
DMF platform for the detection of miR-143 to an LOD of 1.5
femtomoles within 40 min.
A number of research groups have successfully developed
electrochemical biosensors for the sensitive and selective
detection of miRNAs (Figure 3B). Herein, we will focus on
representative examples which are particularly promising for
PoC applications; a recent review by Gillespie et al. (2019)
systematically addresses electrochemical microRNA sensing in
further detail. Electrochemical detection strategies are readily
adaptable to PoC applications due to the availability of low-
cost portable potentiostats (Rowe et al., 2011; Doeven et al.,
2015; Ainla et al., 2018) used in combination with low-cost
commercially available screen printed electrodes or in-house
produced alternatives (Dungchai et al., 2009, 2011).
Cardoso et al. (2016) employed electrochemical impedance
spectroscopy for the determination of miR-155 in human serum
at gold electrodes functionalized with a capture probe and
obtained a detection limit of 5.7 aM from human serum samples.
By developing a four-way junction electrochemical sensor, Labib
et al. (2013a) were able to detect as little as 2 aM of miR-
122 in human serum samples without PCR amplification. In
a subsequent study, the researchers developed a three-mode
duplexed sensor for the detection of two miRNAs – miR-32
and miR-122 – in human serum with a detection limit of
5 aM from 30 µL of sample (Labib et al., 2013b). Gai et al.
(2018) further simplified conventional electrochemical sensing
techniques by developing a two-electrode, self-powered biofuel-
based sensor for the detection of miRNA at 2.7 aM. In an
interesting approach combining electrochemical sensing with
cadmium modified titanium phosphate nanospheres, Cheng et al.
(2015) developed a miRNA-21 sensor with a detection limit of
0.76 aM that could be applied for the direct analysis of human
serum samples (Figure 3B).
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VALIDATION AND TRANSLATION OF
miRNA DIAGNOSTICS
Once a set of miRNAs have been identified as potential disease
biomarkers, their use in a diagnostic assay needs to be adequately
assessed. Accuracy is an oft-cited metric but may not always
be appropriate (for example, if you expect that 99% of the
samples you test are going to be negative, then a test that
simply labels all samples as negative will be 99% accurate).
There are a multitude of other metrics available, including
sensitivity (proportion of infected samples who tested positive),
and specificity (proportion of non-infected samples who tested
negative), all of which are simply different ways of interpreting
a confusion matrix (predicted positive or negative classification
vs. the true classification, see Figure 4A). Another important
performance metric, which has been referenced in some studies,
is the Receiver Operating Characteristic (ROC) curve. A ROC
curve is a graphical representation of how the true positive rate
(TPR) and false positive rate (FPR) change as the classification
threshold is varied between the infected and non-infected groups.
The area under the curve (AUC) is also often calculated, giving
a succinct measure of the overall performance of the test. If a
diagnostic test has zero predictive power, the TPR and FPR will be
equal, resulting in a diagonal line and an AUC of 0.5 (Figure 4B,
Random guess). Alternatively, if it correctly identifies all samples
100% of the time, then the ROC curve, the TPR is equal to 1 and
the FPR is equal to 0, resulting in an AUC of 1.0 (Figure 4B,
Perfect ROC curve). In reality, a diagnostic test usually falls
somewhere between these two possibilities (Figure 4B, Example
ROC curve). A ROC curve can also help choose the classification
threshold. There is a fine balance between the TPR and FPR
and the threshold that is chosen is dependent on the ultimate
purpose of the test. For example, if a patient is exposed to
rabies, it is more acceptable to be falsely identified as infected,
and therefore treated, than falsely identified as not infected,
sent home, and ultimately succumb to infection. Therefore, a
miRNA diagnostic test for rabies infection would heavily favor
the detection of true positives (sensitivity) even if that meant it
detected a larger number of false positives. It is imperative that all
potential diagnostics be evaluated in the context of their use.
Moreover, when translating a miRNA biomarker signature to
a diagnostic device, it is pertinent to have a clear understanding of
how the end consumer will use the test, and how to maximize its
utility. Many current diagnostic tests, such as serology, need to be
sent to a diagnostic laboratory to be analyzed. For infections that
are time-critical this is a costly delay, hence the time it takes to
generate a result is an important consideration. Some diagnostic
platforms may be used for initial screening or used in rural or
remote areas where access to a laboratory is limited. PoC devices
may alleviate these constraints as samples do not need to be
transported to a diagnostic laboratory. In other circumstances
a test undertaken in an accredited diagnostic laboratory may be
more desirable. Regardless of which format the test is ultimately
configured, care needs to be taken to ensure it is fit-for-purpose.
A key step toward final test adoption is evaluation in clinical
trials to define test performance. Tests may be scrutinized at:
FIGURE 4 | Metrics for diagnostic test validation. (A) Example confusion
matrix from which the common metrics (accuracy, sensitivity, and specificity)
can be calculated. (B) ROC graph showing a perfect ROC curve (orange line),
and example ROC curve (blue line), and the diagonal indicating a random
classification model (random guess and black dotted line).
(1) a prototype evaluation (phase I), (2) an evaluation under
ideal conditions (phase II), or (3) an evaluation under real-
life conditions (phase III). At a minimum, such evaluations
should provide information not only on a test’s diagnostic
accuracy but also on its repeatability, reproducibility, and
ease of use. Clinical trials require biomarkers to be assessed
against a gold standard or reference method, often selected
in consultation with regulators during trial design. Clearly,
undertaking clinical trials requires significant financial resources
to enroll patients, disease experts and clinicians, process large
sample numbers and collect clinical data. For some diseases,
particularly emerging infectious diseases, this cost may be
viewed as prohibitive given the market opportunity and expected
return on investment. Gaining access to appropriate samples
or clinical expertise also may present a challenge. The cost of
clinical trials will also be significantly impacted by scope. For
instance, some would argue that in order to demonstrate that
a biomarker-based diagnostic test improves patient outcomes
over an existing or predicate test, a randomized controlled trial
should be conducted. Here, randomized comparisons are made
between two diagnostic interventions (one reference and one
experimental) with identical therapeutic interventions based on
the results of the competing diagnostic tests. Study outcomes
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are clinically important consequences of diagnostic accuracy.
While considered the gold standard, randomized controlled trials
are rarely cited due to their significant costs and a lack of
regulatory pressure.
In addition to clinical trials, navigation through the regulatory
approval process is a key step toward adoption of biomarker-
based diagnostics. The requirements for licensing diagnostic tests
are complex and differs considerably from country to country,
with many lacking regulatory procedures to assess the safety,
quality or effectiveness of in vitro diagnostic tests (IVDs). In
the United States, the Food and Drug Administration (FDA)
regulates IVDs with the intended use of the device determining
how much data, type of data, and approval route to use. Within
Europe the European Medicine Association (EMA) fulfills this
role. Whether or not the biomarker test is substantially equivalent
to an existing test, and the context in which a test will be
used (critical versus low or moderate risk) are factors in the
level of regulation and data required. Additionally, the sample
type and route of collection will impact the ease of use and
clinical uptake of an IVD. Less invasive samples, such as saliva
or sputum are often preferred over blood or sera. Indeed,
miRNAs have been found in almost all biofluids, including saliva
(Min et al., 2018), urine (Ben-Dov et al., 2014), breast milk
(Kelleher et al., 2019), and tears (Kim et al., 2019), however,
the use of these less invasive sample types would depend on
the underlying disease. For example, salivary miRNAs may
be useful for the diagnosis of mouth infections (Min et al.,
2018) but may not be useful for infections in other areas
of the body. Blood, serum, and plasma are often used for
biomarker identification as peripheral samples often contain
markers of localized disease. Consideration for disease pathology
and clinical practice must be taken when looking to translate
miRNA biomarkers.
While the market for miRNA biomarkers is still in its
infancy, some products (primarily in oncology) are currently
available to clinicians, while others are entering pre-clinical
and clinical trials (Bonneau et al., 2019). Interpace Diagnostics
is one notable example, with their product ThyraMIR R© (a 10
miRNA panel) distinguishing between benign and malignant
thyroid cancer. This test is combined with an oncogene NGS
panel (ThyGeNEXT R©) to stratify patients on whether they require
surgery and if so, the extent of the surgical intervention. This
approach, first detailed in 2015 (Labourier et al., 2015), has
since been refined and demonstrates significant clinical utility
in stratifying patients based on their risk of malignancy after
9 months (Sistrunk et al., 2020). Interpace Diagnostics has also
been successful in obtaining coverage for these tests by some
of the largest health insurance providers in the United States, a
significant step in clinical adoption. Case studies such as this can
provide invaluable insight into the journey of miRNA biomarkers
from discovery to clinical application.
CONCLUSION
For many infectious diseases, the current diagnostic technologies
are inadequate. Many rely on the presence of symptoms or
pathogen-specific antibodies or cannot be utilized until the
pathogen has replicated to a detectable titer. New biomarkers
are sorely needed to underpin the next generation of diagnostic
platforms. MicroRNAs have substantial potential as biomarkers
of infection, as evident in the growing body of research data.
These molecules are altered in biofluids due to infections
with bacteria, parasites, viruses, and even prions. Their use as
diagnostic or prognostic markers is not without its challenges,
however, with robust analytical and validation methods, their
use may alleviate the shortcomings of current tests, leading
to improved patient outcomes. In conjunction with the
identification of sufficiently predictive miRNAs, the exciting
progress in miRNA sensing technologies and the emergence of
recent, commercially available miRNA-based diagnostics, means
that miRNAs will inevitably be employed as powerful new tools
in diagnostic, prognostic and even therapeutic strategies for
infectious diseases.
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